|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 785.92 USD | +1.06% |
|
+1.07% | +2.02% |
| 03:38pm | Sector Update: Health Care | MT |
| 11:04am | Öhman Health and New Technology Fund Rises 3.9% in June - Camurus Surges After Eli Lilly Partnership | FW |
| Capitalization | 698B 596B 556B 514B 957B 59,847B 1,069B 6,651B 2,531B 27,960B 2,619B 2,564B 102,303B | P/E ratio 2025 * |
36.6x | P/E ratio 2026 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise value | 723B 618B 575B 532B 991B 61,973B 1,107B 6,888B 2,621B 28,953B 2,712B 2,655B 105,938B | EV / Sales 2025 * |
12.1x | EV / Sales 2026 * | 9.93x |
| Free-Float |
99.81% | Yield 2025 * |
0.76% | Yield 2026 * | 0.85% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +1.11% | ||
| 1 week | +1.07% | ||
| Current month | +1.03% | ||
| 1 month | +1.79% | ||
| 3 months | +4.49% | ||
| 6 months | -1.54% | ||
| Current year | +2.02% |
| 1 week | 762.03 |  | 794 |
| 1 month | 755.56 | | 825 |
| Current year | 677.09 | | 935.62 |
| 1 year | 677.09 | | 972.53 |
| 3 years | 296.32 | | 972.53 |
| 5 years | 129.21 | | 972.53 |
| 10 years | 64.18 | | 972.53 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 65 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 2009-03-31 |
| Director/Board Member | 53 | 2011-12-11 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 6.49% | 21 M€ | +3.63% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.07% | +1.07% | -15.54% | +137.89% | 698B | ||
| -0.03% | +0.12% | +5.91% | -12.67% | 375B | ||
| +0.41% | -0.20% | +13.28% | +24.24% | 335B | ||
| -1.53% | +0.35% | -54.14% | +9.26% | 313B | ||
| +0.89% | -0.04% | +6.30% | -20.36% | 259B | ||
| -0.16% | -0.89% | +0.47% | +17.53% | 240B | ||
| +0.21% | -0.27% | -13.25% | -7.10% | 217B | ||
| +3.01% | +1.78% | -33.47% | -11.08% | 204B | ||
| -0.14% | +0.01% | -6.03% | +19.81% | 160B | ||
| -0.53% | +0.63% | -8.08% | -51.82% | 146B | ||
| Average | +0.29% | +0.74% | -10.45% | +10.57% | 294.8B | |
| Weighted average by Cap. | +0.37% | +0.50% | -10.60% | +31.64% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 59.78B 51.07B 47.59B 44.01B 81.92B 5,125B 91.57B 570B 217B 2,394B 224B 220B 8,760B | 71.51B 61.09B 56.93B 52.65B 97.99B 6,131B 110B 681B 259B 2,864B 268B 263B 10,480B |
| Net income | 19.22B 16.42B 15.3B 14.15B 26.33B 1,647B 29.44B 183B 69.67B 770B 72.08B 70.59B 2,816B | 25.28B 21.59B 20.12B 18.61B 34.64B 2,167B 38.72B 241B 91.65B 1,012B 94.82B 92.86B 3,705B |
| Net Debt | 24.8B 21.19B 19.75B 18.26B 33.99B 2,126B 38B 236B 89.92B 993B 93.04B 91.11B 3,635B | 12.25B 10.46B 9.75B 9.02B 16.78B 1,050B 18.76B 117B 44.39B 490B 45.93B 44.98B 1,794B |
More financial data
* Estimated data
Employees
47,000
Sector
Pharmaceuticals
Calendar
Aug. 07
- Q2 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-09 | 787.23 $ | +1.23% | 1,739,927 |
| 25-07-08 | 777.66 $ | +0.62% | 3,301,776 |
| 25-07-07 | 772.87 $ | -1.00% | 2,576,881 |
| 25-07-03 | 780.67 $ | +0.18% | 1,450,772 |
| 25-07-02 | 779.28 $ | +0.44% | 1,978,285 |
Delayed Quote Nyse, July 09, 2025 at 03:27 pm EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
777.66USD
Average target price
951.98USD
Spread / Average Target
+22.42%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
Select your edition
All financial news and data tailored to specific country editions
